Workshop: An ANTIDotE for tick borne diseases 3rd of June 2016.
The last ANTIDotE workshop was held in Potsdam, Germany. Leading researchers from academic institutions, pharmaceutical companies and public agencies from all over Europe, Africa and Northern America attended the workshop. The combination of an open atmosphere, interesting presentations and impassioned attendees resulted in fruitful discussions, making the workshop a great success! We want to thank everyone for their input.
ANti-tick vaccines to prevent TIck-borne Diseases in Europe.
ANTIDotE is a consortium of 7 European research institutes funded by the European Commssion to investigate anti-tick vaccines. Our objective is to identify and characterize tick salivary gland proteins involved in tick feeding and tick-borne pathogen transmission, and to use this knowledge to develop and assess anti-tick vaccines to prevent multiple human tick-borne diseases.
The ANTIDotE consortium consists of 7 European participants, and an advisory board with 7 partners with different backgrounds and networks. This enables ANTIDotE to achieve its groundbreaking objectives.
For more information on the participants see the participants section of this website. The advisory board consists of Yale University (Yale), the Research Institite for Wildlife Health in Europe (Artemis), the Friedrich-Loeffler Institute (FLI), the National Institute of Public Health from the Czech Republic (NIPH CZ), Nationa Public Health Institute of Slovenia (NPHI SL), Center for Tick-borne Diseases in Hungary (CTB) and Theo Schetters (current protActivity and former Merck, Sharp & Dohme (MSD).